Status of the Quality System Team – June 27, 2025
Since the last TraCe-bMPS update in April, we continued to explore different conditions to optimize the μSiM hVasc-SkM systems to obtain stable results. Enhanced imaging for PDMS beams with Rhodamine staining Previously we established a MATLAB program that detects the border of the PDMS beams and converts the movement of the PDMS beam from myobundle…
Introduction Over the past few months, I have been characterizing and comparing iPSC-derived monocytes (iMonocytes) with peripheral blood-derived (PB) monocytes. As I wrap up these experiments, we’ve decided to look at marker expression on iMonocytes and PB monocytes once they have been polarized to macrophages by culturing the iMonocytes or PB monocytes with HTEN051 fibroblasts…
CRE_Bispecific_Antibody_CRS_and_ICANS_Neurotoxicity_Guidance_Feb2024 51899285fnl_Immunotoxic Potential of PharmaceuticalsWe are considering Bispecific T cell engagers (BiTEs) [1] as an alternative to a CAR T driven cytokine release as an immunotherapy focused DDT. BiTEs are monoclonal antibodies engineered to have one arm that recognizes a T Cell surface antigen and another that recognizes a tumor antigen. There are number of…
Introduction Our goal was to develop a COMSOL model for the bottom channel of the µSiM that can be accessed and easily used by anyone with a COMSOL license. Previously developed simulations for the µSiM rely on the CAD import module, which can introduce unnecessary complications with regards to accessibility and ease-of-use, particularly to expand…
Image analysis for force from videos of deflected PDMS beams In the summer, Yimei Du from University of Rochester visited Truskey lab to help with the μSiM Vasc-SkM system. Besides working with the chip culture, she helped improve the image analysis of the videos of PDMS beam deflection for more accurate myobundle force analysis. We…
Work in progress … **************** T cell–Engaging Immunotherapies Pose a Predictable but Complex RiskT cell–engaging bispecific antibodies (BsAbs), particularly those targeting CD3 and a tumor-associated antigen, have emerged as a powerful class of immunotherapies. These agents leverage endogenous T cells to induce targeted tumor cell death, often achieving deep and durable responses in hematologic malignancies….